Supplementary Table from Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER&lt;sup&gt;+&lt;/sup&gt; Breast Cancer Patient-derived Xenograft Models